Who Paid My Doc
Karam Mounzer
Infectious Disease Philadelphia, PA Medical Doctor
NPI 1265571152 CMS profile 239323
1233 Locust St Fl 4, Philadelphia, PA 19107
General payments
$711,872
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$864,810
Through program year 2025, Karam Mounzer of Philadelphia, PA is reported in the CMS Open Payments database as having received $711,872 across 982 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $864,810 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $116,765 | 166 | |
| 2024 | General | $92,768 | 132 | |
| 2023 | General | $81,872 | 159 | |
| 2022 | General | $91,360 | 116 | |
| 2021 | General | $65,198 | 82 | |
| 2020 | General | $98,834 | 94 | |
| 2019 | General | $165,074 | 233 |
Beside peers
- Karam Mounzer
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Karam Mounzer were reported at $116,765. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Karam Mounzer | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $165,074 | $190 | $60–$862 | $163 |
| 2020 | $98,834 | $124 | $32–$606 | $114 |
| 2021 | $65,198 | $148 | $38–$905 | $132 |
| 2022 | $91,360 | $166 | $50–$834 | $149 |
| 2023 | $81,872 | $171 | $57–$787 | $160 |
| 2024 | $92,768 | $176 | $52–$752 | $164 |
| 2025 | $116,765 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 145 drugsPart D claims
6,348
Drug cost
$5,513,790
Branded share of claims
46.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 352 | $1,422,597 | |
| Tivicay Dolutegravir Sodium | Brand | 239 | $631,187 | |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | Brand | 119 | $497,019 | |
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 200 | $443,444 | |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | Brand | 76 | $356,237 | |
| Dovato Dolutegravir Sodium/Lamivudine | Brand | 107 | $323,360 | |
| Prezcobix Darunavir/Cobicistat | Brand | 102 | $268,173 | |
| Triumeq Abacavir/Dolutegravir/Lamivudi | Brand | 38 | $169,652 | |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | Brand | 42 | $155,221 | |
| Egrifta Sv Tesamorelin Acetate | Brand | 19 | $139,410 |
The 10 drugs with the highest cost, of 145 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 13 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| RUKOBIA |
|
$32,890 | 12 | — |
| Biktarvy |
|
$21,506 | 352 | — |
| DOVATO |
|
$4,723 | 107 | — |
| PIFELTRO |
|
$3,467 | 57 | — |
| TROGARZO |
|
$3,104 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 13 in the dashboard with a free accountRecords
982 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in Pennsylvania
Related records
Infectious Disease in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.